TY - JOUR
T1 - An analysis of FDA-approved drugs for neurological disorders
AU - Kinch, Michael S.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2015/9/9
Y1 - 2015/9/9
N2 - Neuroscience remains a great challenge and opportunity in terms of new drug discovery and development. An assessment of FDA-approved new molecular entities (NMEs) reveals a low steady rate of new FDA approvals, which is interrupted by two bursts in activity, first in the 1950s and then in the 1990s. These trends are reflected in the approvals for NMEs targeting multiple indications in this field, including seizure, Parkinson's disease and neuromuscular disorders. The majority of drugs target ion channels or G-protein-coupled receptors (GPCRs) but the mechanistic basis for many NMEs remains unclear or controversial. These trends could suggest future opportunities for success in a crucial field with considerable unmet needs.
AB - Neuroscience remains a great challenge and opportunity in terms of new drug discovery and development. An assessment of FDA-approved new molecular entities (NMEs) reveals a low steady rate of new FDA approvals, which is interrupted by two bursts in activity, first in the 1950s and then in the 1990s. These trends are reflected in the approvals for NMEs targeting multiple indications in this field, including seizure, Parkinson's disease and neuromuscular disorders. The majority of drugs target ion channels or G-protein-coupled receptors (GPCRs) but the mechanistic basis for many NMEs remains unclear or controversial. These trends could suggest future opportunities for success in a crucial field with considerable unmet needs.
UR - http://www.scopus.com/inward/record.url?scp=84941021907&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2015.02.003
DO - 10.1016/j.drudis.2015.02.003
M3 - Short survey
C2 - 25681791
AN - SCOPUS:84941021907
SN - 1359-6446
VL - 20
SP - 1040
EP - 1043
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 9
ER -